CompletedNCT02974010
Sequential Treatments for Suicidal Thoughts in Bipolar Depression
About this title
Sequential Therapy for the Treatment of Severe Bipolar Depression.
Read the official source — NCT02974010Medication studyAges 18–65United StatesBipolarity
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Birmingham and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: January 15, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 22
- Sponsor
- NeuroRx, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02974010
- Official title
Show the full official title
Sequential Therapy (NRX-100 Followed by NRX-101) for the Treatment of Acute Suicidal Ideation and Behavior in Bipolar Depression: the STABIL-B Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Birmingham · Fort Lauderdale · Charlotte
1 more locations
- Houston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is NeuroRx, Inc.
Did this study involve medication?
Yes. The study involved medication, including NRX-101 Oral Capsule, Lurasidone Oral Capsule, Ketamine Intravenous Infusion and Saline Solution Intravenous Infusion.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
